Observational studyLiver international : official journal of the International Association for the Study of the Liver2026
Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort.
Observational study in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Time-Varying Impact of Steatosis and Alcohol on Mortality: A Marginal Structural Model of the Canadian Longitudinal Study on Aging.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Revisiting Obesity Definitions: Impact of the 2025 Lancet Commission Criteria on Obesity Prevalence Among People With MASLD.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Distinct Roles of Myeloid- and Hepatocyte-PLA2G6 Deletion in Mice With Metabolic Dysfunction-Associated Steatotic Liver Disease.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Unveiling the Burden of Steatotic Liver Disease: Mortality Risks by Subtype and Fibrosis Stage in a Nationwide Cohort.Liver international : official journal of the International Association for the Study of the Liver · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
aimsWe investigated the associations between SLD, fibrosis stage, and all-cause and cause-specific mortality, with a focus on SLD subtypes.
methodsWe analysed 486 156 UK Biobank participants. SLD cases were identified using fatty liver index ≥ 60. Causes of death were confirmed via death registries. Multivariable Cox models estimated associations between SLD, SLD subtypes, FIB4 score and mortality outcomes, including all-cause mortality, mortality from liver-related diseases, cardiovascular disease (CVD) and extrahepatic cancers.
resultsSLD was identified in 178 336 participants (36.7%): 73.5% with MASLD, 19.0% with MetALD and 6.4% with ALD. Over a median follow-up of 13.8 years, 20 766 (11.6%) deaths occurred among people with SLD and 21 754 among those without (307 820; 7.1%), suggesting a higher mortality rate in SLD than in non-SLD (8.78 vs. 5.25/1000 person-years). All SLD subtypes were associated with higher all-cause mortality: MASLD (HR (95% CI): 1.32 (1.29-1.35)), MetALD (1.16 (1.12-1.20)) and ALD (1.36 (1.29-1.44)). Excess mortality was primarily driven by extrahepatic cancer (42.5%) and cardiovascular disease (24.2%), while liver-related deaths were concentrated among those with ALD and fibrosis. A strong dose-response relationship was observed between FIB4 stratification and mortality, particularly for liver-related deaths. These associations were independent of socioeconomic status, lifestyle and cardiometabolic risk factors.
conclusionSLD is independently associated with increased all-cause and cause-specific mortality, with substantial variation across subtypes and fibrosis severity. Extrahepatic cancer and cardiovascular disease are the leading contributors to excess mortality. These findings underscore the need for integrated care strategies targeting metabolic risk, fibrosis progression and cancer prevention in the SLD population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.